1. ALLA AKTIER
  2. NYHETER
  3. LIPUM

Lipum

Nyheter Lipum Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Lipum Announces Outcome of Warrant Programs TO A 2025/2028 and TO B 2025/2028

Lipum AB (publ) today announces the allocation of warrants in series TO A 2025/2028 and TO B 2025/2028, as resolved at the company’s Annual General Meeting held on June 16, 2025.

During the period June 16 - 30, employees, key consultants, and board members were given the opportunity to subscribe for warrants in Lipum at a price of SEK 2.72 per warrant.

Outcome:

  • Number of subscribed warrants: 150,000
  • Total number of warrants offered: 168,000
  • Subscription rate: 89%
  • Number of warrants reserved for future use: 44,000 (62,000)
  • Lipum will thus receive approximately SEK 408,000

CEO Comment:
"I am very pleased with the strong interest in the warrant programs and the confidence in Lipum's operations shown by our employees and board members “ said Ola Sandborgh, CEO

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum Announces Outcome of Warrant Programs TO A 2025/2028 and TO B 2025/2028

Datum 2025-07-08, kl 08:30
Källa MFN
Bifogade filer
Lipum Announces Outcome of Warrant Programs TO A 2025/2028 and TO B 2025/2028